Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi - Wikidata - awgldk - TriplyDB

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

http://www.wikidata.org/entity/Q34624438

about

Chemotherapy for downstaging unresectable liver metastases from colorectal cancer Surgical resection versus non-surgical treatment for hepatic node positive patients with colorectal liver metastases Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives Evolution of management in peritoneal surface malignancies Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer Treatment of peritoneal metastases from colorectal cancer Anti-angiogenic agents in metastatic colorectal cancer Therapeutic strategies for synchronous and multiple liver metastases from colorectal cancer Role of surgery in colorectal cancer liver metastases Review of systemic therapies for locally advanced and metastatic rectal cancer How to select the optimal treatment for first line metastatic colorectal cancer FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases Role of targeted therapy in metastatic colorectal cancer Multisciplinary management of patients with liver metastasis from colorectal cancer RAS and BRAF in metastatic colorectal cancer management FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer Effect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cells Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer.Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.Oral drugs in the treatment of metastatic colorectal cancer."Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist.'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome.A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases.Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance Effect of glutathione combined with cisplatin and oxaliplatin on the proliferation and apoptosis of lung carcinoma cell line.Colorectal cancer: from prevention to personalized medicine.Current status of pharmacological treatment of colorectal cancer.Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series.Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.Multidisciplinary approach of colorectal cancer liver metastases.Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases.Targeting metastatic colorectal cancer - present and emerging treatment options Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.

P2860

Q24234615-A8796FF4-2640-43F6-BDF9-517D901867DC Q24241019-5F3F775C-5A22-4327-8D47-1444C471C778 Q26738655-C881368D-1F8C-4B09-A377-66C2FCF6CFB5 Q26738801-ED5F3BE7-A602-4A07-8FD9-6D471CD8D8AD Q26741293-DC289FB0-024F-4863-A65C-B2431FA9EDD9 Q26774704-E3226428-415C-47F9-9FE7-5D5C1C7CAE9E Q26775949-12DF6CEF-790A-409F-BDF8-3594B57DBF36 Q26783662-1929034E-2D68-4DF3-BA4A-46B2814E1B69 Q26801911-BB8FD2A7-7C1A-4AFB-966E-91D2F03D86E5 Q26829522-0E36B0FE-75BB-4498-BC12-FB2CC49A07E7 Q26830444-1E2CB2AC-F4D6-4471-AF9A-D6E8E733DEB0 Q27021105-72CF1828-D04E-420A-8C7E-6CA474299C14 Q27026516-A3BCC934-5258-45D8-BB85-F3033132039F Q28066171-9677B56D-A44D-48BF-B793-46074396EFE8 Q28067408-A209D786-5E4C-4FCA-9ABA-770B4E4C3625 Q28068817-3DDE9E7F-F3BC-4623-9890-BB180BC296A4 Q28069575-6C082BCC-8427-4BE5-9BA3-EED71434F5A3 Q28074175-5B8DE164-3093-4491-92DB-077C7916308B Q28075540-15C9C359-0C8B-4C6D-8A43-4D23E448ECFE Q28468621-DEE5EF93-A536-4B6E-AC07-9335A9E0B0E5 Q28652334-C1E2927F-A869-4704-A374-682EDFA36BFF Q30239825-0AA6C3A0-EFAD-4D02-A21F-5CACFF58C6E9 Q30244769-B5CBFFF9-338C-4374-8A79-E3A09F2BDEF3 Q30251387-4396B40B-E004-4799-8C8D-E52CDE83518F Q30990540-4CE38E69-10C5-4AAE-A0D2-4A35EBBAE22B Q31168985-12C39050-5B47-42AB-9CE2-796BC079B8A2 Q33515915-6C11D451-798B-480D-88B6-97BD9483827D Q33555283-FB625D99-DE5D-4F4B-9394-34A1B8B7CFE1 Q33579145-9BC70960-E933-4892-84B1-32C1D69A294D Q33627739-D893C680-6930-4ECD-BCA4-401295A43F2B Q33693186-10AAAF84-4C0D-4317-9335-0802E17CB06D Q33735234-2B765A0C-8032-419B-9091-FC1E6125A6C5 Q33759532-13BEEAAA-C8AF-4F10-9DCC-A74A81B9DA72 Q33777340-909EC0D0-5666-4E61-96C4-810A38E66286 Q33777576-160294F4-01DC-47EA-9E88-EC57854FDD98 Q33779859-F16CF126-7D91-4094-BA4B-B3DE6504CA50 Q33873948-8C847D3A-E47F-4826-9765-E220E4576BF5 Q33909911-A54B0BFB-7F3B-473E-86C4-4F9FCD9C4CC9 Q33970042-2710C0AB-5EBF-4FCB-8256-350D41E3BB80 Q34005111-BFE9FF4E-FAB3-49E6-9329-5136227C1925

P2860

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

http://www.wikidata.org/entity/Q34624438

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@ast

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@en

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@nl

type

label

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@ast

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@en

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@nl

prefLabel

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@ast

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@en

Phase III trial of infusional ...... al cancer: the Gruppo Oncologi

@nl

P1433

Q34624438-001EA2B7-85B5-44D9-94C3-817E5E64DFCD

P1476

Q34624438-D79E606A-22E7-49B6-9699-7E961444D049

P2093

Q34624438-08F746AC-275C-47F9-9775-7CAF50D536A4

Q34624438-149F8639-A258-4109-BE10-73490AF6EFFD

Q34624438-170904C8-7D6B-434D-B7A3-7E6C7CBD2199

Q34624438-20110BE5-B2D0-487E-9720-92F5DFA79D60

Q34624438-2AD125DB-ED0A-475F-8F2B-7FBCEF394412

Q34624438-4C9110E9-AFAA-47FD-924E-2BA52874842E

Q34624438-50310FC2-34C5-4E27-A051-53A93214E938

Q34624438-64644172-825F-4AAF-A1C4-546ABC490DC0

Q34624438-6B65FCD7-BADC-408E-8C8C-696BA6C39CAC

Q34624438-7340F607-F505-48D0-8BC8-BBCC80C287CF

P304

Q34624438-69B72BC6-773E-4461-8ECB-9B52931FE980

P31

Q34624438-80C16EC6-3889-4E4E-B191-7B68FD6D334B

P356

Q34624438-A545A7DA-FD6A-4853-AB20-6D03AEA7A54A

P407

Q34624438-99005C85-FB4C-4C68-967A-D9CA3B6C5ED9

P433

Q34624438-34CABD81-08C2-4A5B-B2B5-2C183C70810F

P478

Q34624438-77370CC1-EEAC-4790-9646-FAB97971FEAF

P50

Q34624438-85FAA688-15FB-48F6-9354-45E0F133A550

P577

Q34624438-17A06A7D-935C-49A2-8844-E0F5A7CC51A3

P698

Q34624438-93648CF7-907A-46F0-8EC2-74BEB7AFE564

P921

Q34624438-29E580EB-7BE3-4C3F-9CA4-061B55F5A2B4

Q34624438-F7EDDBEB-B8DB-4A89-9CEB-090BFE502F88

P356

JCO.2006.09.0928

P1433

Journal of Clinical Oncology

P1476

Phase III trial of infusional ...... e Gruppo Oncologico Nord Ovest

@en

P2093

Cecilia Barbara

http://www.w3.org/2001/XMLSchema#string

Cinzia Orlandini

http://www.w3.org/2001/XMLSchema#string

Cristina Granetto

http://www.w3.org/2001/XMLSchema#string

Elisabetta Pfanner

http://www.w3.org/2001/XMLSchema#string

Enrico Cortesi

http://www.w3.org/2001/XMLSchema#string

Giacomo Allegrini

http://www.w3.org/2001/XMLSchema#string

Gianfranco Porcile

http://www.w3.org/2001/XMLSchema#string

Gianluca Masi

http://www.w3.org/2001/XMLSchema#string

Giovanni Benedetti

http://www.w3.org/2001/XMLSchema#string

Gruppo Oncologico Nord Ovest

http://www.w3.org/2001/XMLSchema#string

P304

1670-1676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.09.0928

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Alfredo Falcone

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17470860

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase III clinical trial